**Question:** Lovastatin acts by inhibiting

A. HMG-CoA reductase
B. Cytochrome P450 enzymes
C. Carbonic anhydrase
D. L-type calcium channels

**Core Concept:** Lovastatin is a statin drug used in the management of hyperlipidemia and prevention of cardiovascular events in patients with established cardiovascular disease or high risk for cardiovascular events. Statins work by inhibiting the enzyme HMG-CoA reductase, which is a key enzyme in the mevalonate pathway, leading to cholesterol synthesis reduction.

**Why the Correct Answer is Right:** Lovastatin inhibits HMG-CoA reductase (Option A), which is the rate-limiting enzyme in the mevalonate pathway. This pathway is involved in the synthesis of cholesterol, and inhibiting this enzyme reduces cholesterol production, resulting in a decrease in plasma cholesterol levels and a reduction in cardiovascular risk.

**Why Each Wrong Option is Incorrect:**

B. Cytochrome P450 enzymes (Option B) are involved in the biotransformation of drugs, not cholesterol synthesis. Lovastatin does not inhibit these enzymes; instead, it is a substrate for them.

C. Carbonic anhydrase (Option C) is an enzyme responsible for catalyzing the hydration of carbon dioxide, not involved in cholesterol synthesis.

D. L-type calcium channels (Option D) are involved in regulating intracellular calcium levels, not cholesterol synthesis. Lovastatin does not act on these channels; it targets HMG-CoA reductase instead.

**Clinical Pearl:** The correct option (A) highlights the importance of understanding the pharmacology of statins in managing hyperlipidemia and preventing cardiovascular events. This helps physicians select appropriate treatments for patients with lipid disorders and assess the potential side effects of statin therapy, which include myopathy and myositis.